J
Jeffrey J. Annon
Researcher at University of California, Los Angeles
Publications - 18
Citations - 837
Jeffrey J. Annon is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Buprenorphine & Naloxone. The author has an hindex of 12, co-authored 18 publications receiving 783 citations. Previous affiliations of Jeffrey J. Annon include National Institute on Drug Abuse & Semel Institute for Neuroscience and Human Behavior.
Papers
More filters
Journal ArticleDOI
A multi-center randomized trial of buprenorphine–naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
Walter Ling,Leslie Amass,Steve Shoptaw,Jeffrey J. Annon,Maureen Hillhouse,Dean Babcock,Greg Brigham,Judy Harrer,Malcolm S. Reid,Joan A. Muir,Betty J. Buchan,Debbie Orr,George E. Woody,Jonathan Krejci,Douglas M. Ziedonis +14 more
TL;DR: The benefits of bup-nx for opioid detoxification are supported and illustrate important ways in which clinical research can be conducted in community treatment programs.
Journal ArticleDOI
Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience
Leslie Amass,Walter Ling,Thomas E. Freese,Chris Reiber,Jeffrey J. Annon,Allan Cohen,Dennis McCarty,Malcolm S. Reid,Lawrence S. Brown,Cynthia Clark,Douglas M. Ziedonis,Jonathan Krejci,Susan M. Stine,Theresa Winhusen,Greg Brigham,Dean Babcock,Joan A. Muir,Betty J. Buchan,Terry Horton +18 more
TL;DR: Data from the CTN field experience suggest that buprenorphine-naloxone is practical and safe for use in diverse community treatment settings, including those with minimal experience providing opioid-based pharmacotherapy and/or medical detoxification for opioid dependence.
Journal ArticleDOI
Buprenorphine tapering schedule and illicit opioid use
Walter Ling,Maureen Hillhouse,Catherine P. Domier,Geetha Doraimani,Jeremy Hunter,Christie Thomas,Jessica Jenkins,Albert Hasson,Jeffrey J. Annon,Andrew J. Saxon,Jeffrey Selzer,Joshua Boverman,Richard Bilangi +12 more
TL;DR: For individuals terminating buprenorphine pharmacotherapy for opioid dependence, there appears to be no advantage in prolonging the duration of taper.
Journal ArticleDOI
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence
Douglas M. Ziedonis,Leslie Amass,Marc L. Steinberg,George E. Woody,Jonathan Krejci,Jeffrey J. Annon,Allan Cohen,Nancy Waite-O’Brien,Susan M. Stine,Dennis McCarty,Malcolm S. Reid,Lawrence S. Brown,Robert Maslansky,Theresa Winhusen,Dean Babcock,Greg Brigham,Joan A. Muir,Deborah Orr,Betty J. Buchan,Terry Horton,Walter Ling +20 more
TL;DR: Medication type (buprenorphine-naloxone) was the most important predictor of positive outcome; however the paper also considers other clinical and policy implications of other results, including that inpatient setting predicted better outcomes and moderated medication outcomes.
Journal ArticleDOI
HIV Risk Behaviors among Women in Methadone Maintenance Treatment
TL;DR: Risk behaviors for HIV were associated with age, lack of education, ethnicity, relationship with a drug user, HIV status, and higher scores on measures of illegal activity, suicidality, depression, polydrug use, and alcohol use.